Pharmacosmos to join the 9th Congress of ECCO

November 18, 2013

Pharmacosmos to join the 9th Congress of ECCO Inflammatory Bowel Diseases 2014 in Copenhagen.

Pharmacosmos will join the 9th Congress of ECCO Inflammatory Bowel Diseases 2014, to be held in Copenhagen February 20-22, 2014.

Pharmacosmos will participate with a booth and will also be hosting a satellite symposium entitled "Optimising iron treatment for IBD patients - NEW clinical data and a NEW e-tool," on Thursday 20th. February at 11:30 am.

ECCO is the European Crohn's and Colitis Organisation and the congress is the major European educational event in the field of Inflammatory Bowel Diseases (IBD) and has achieved large popularity across the world.

ECCO 2014 in Copenhagen will provide a unique opportunity to gain access to the latest and best scientific information and education in adult and paediatric gastroenterology, hepatobiliary disease, endoscopy, imaging, gastrointestinal surgery related to IBD.

The congress aims are to advance the understanding of digestive disorders, to improve the development of guidelines through the most robust process, to define better and valid outcomes for the therapy of IBD, all to enhance patient care. By promoting research, integrating basic science and clinical practice, fostering international collaboration and friendship, IBD experts strive to bring hope and comfort to the many people who suffer from IBD.

Please visit for further information.



About Pharmacosmos A/S

Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more than 50 years of innovation and leadership in iron- and carbohydrate-based treatments and solutions for human and animal use.

A research-based company, its ongoing R&D programme focuses on improving the lives of patients with iron deficiency with or without anaemia. More than 1 billion people live with iron deficiency anaemia and it is the leading cause of death for an estimated 180,000 people every year. This makes it one of the largest global health challenges of our time.

Pharmacosmos has subsidiaries in the Nordics, the UK and the US and its products are marketed in more than 80 countries across the world. Its manufacturing facilities are approved, among others, by the Danish Medicines Agency and the US FDA.